{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:25Z","timestamp":1791357205444,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/npp.2010.79","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T14:15:39Z","timestamp":1276697739000},"page":"2072-2082","source":"Crossref","is-referenced-by-count":115,"title":["A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia"],"prefix":"10.1038","volume":"35","author":[{"given":"Henry A","family":"Nasrallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Gassmann-Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"BFnpp201079_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672\u2013676.","journal-title":"Br J Psychiatry"},{"key":"BFnpp201079_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0924-977X(03)00109-3","volume":"14","author":"NH Bhanji","year":"2004","unstructured":"Bhanji NH, Chouinard G, Margolese HC (2004). A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 14: 87\u201392.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFnpp201079_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4088\/JCP.v68n0601","volume":"68","author":"D Cooper","year":"2007","unstructured":"Cooper D, Moisan J, Gregoire JP (2007). Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 68: 818\u2013825.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201079_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P et al (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93: 117\u2013130.","journal-title":"Schizophr Res"},{"key":"BFnpp201079_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.psychres.2006.02.006","volume":"144","author":"FD Gianfrancesco","year":"2006","unstructured":"Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH (2006). Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 144: 177\u2013189.","journal-title":"Psychiatry Res"},{"key":"BFnpp201079_CR6","doi-asserted-by":"crossref","unstructured":"Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM et al (2010). Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Intl Clin Psychopharm (e-pub ahead of print 10 April 2010).","DOI":"10.1097\/YIC.0b013e32833948fa"},{"key":"BFnpp201079_CR7","first-page":"534","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W (1976). AIMS. In: Guy W (ed). ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare: Rockville, MD. pp 534\u2013537."},{"key":"BFnpp201079_CR8","first-page":"285S","volume-title":"In Biol Psych","author":"D Hough","year":"2008","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M (2008). Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized,double-blind, placebo-controlled study. In Biol Psych. Society of Biological Psychiatry (SOBP), Washington, DC USA, pp 285S\u2013286S."},{"key":"BFnpp201079_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","volume":"33","author":"D Hough","year":"2009","unstructured":"Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V et al (2009). Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 1022\u20131031.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp201079_CR10","unstructured":"Intralipid (2007). (prescribing information) Fresenius Kabi AB Uppsala, Sweden."},{"key":"BFnpp201079_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P et al (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90: 147\u2013161.","journal-title":"Schizophr Res"},{"issue":"Suppl 12","key":"BFnpp201079_CR12","first-page":"5","volume":"64","author":"JM Kane","year":"2003","unstructured":"Kane JM, Leucht S, Carpenter D, Docherty JP (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 (Suppl 12): 5\u201319.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201079_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.4088\/JCP.v64n1105","volume":"64","author":"SJ Keith","year":"2003","unstructured":"Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64: 1308\u20131315.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201079_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y et al (2010). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Intl J Neuropsychopharm 13: 635\u2013647.","journal-title":"Intl J Neuropsychopharm"},{"key":"BFnpp201079_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","volume":"27","author":"M Kramer","year":"2007","unstructured":"Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P et al (2007). Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharm 27: 6\u201314.","journal-title":"J Clin Psychopharm"},{"key":"BFnpp201079_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"issue":"22 Suppl 8","key":"BFnpp201079_CR17","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/ajhp\/59.suppl_8.S10","volume":"59","author":"RC Love","year":"2002","unstructured":"Love RC (2002). Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 59 (22 Suppl 8): S10\u2013S15.","journal-title":"Am J Health Syst Pharm"},{"key":"BFnpp201079_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","volume":"22","author":"R Luthringer","year":"2007","unstructured":"Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K et al (2007). A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 22: 299\u2013308.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFnpp201079_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M et al (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62: 1363\u20131370.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201079_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1055\/s-2007-992140","volume":"40","author":"TD Marinis","year":"2007","unstructured":"Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A et al (2007). Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40: 257\u2013263.","journal-title":"Pharmacopsychiatry"},{"key":"BFnpp201079_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323\u2013329.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp201079_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4088\/JCP.v65n0412","volume":"65","author":"HA Nasrallah","year":"2004","unstructured":"Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M (2004). Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65: 531\u2013536.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201079_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","volume":"115","author":"HA Nasrallah","year":"2007","unstructured":"Nasrallah HA (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115: 260\u2013267.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp201079_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","volume":"161","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah H, Morosini P, Gagnon DD (2008). Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 161: 213\u2013224.","journal-title":"Psychiatry Res"},{"key":"BFnpp201079_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1185\/03007990802611919","volume":"25","author":"DL Patrick","year":"2009","unstructured":"Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D et al (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 25: 325\u2013338.","journal-title":"Curr Med Res Opin"},{"key":"BFnpp201079_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11\u201319.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BFnpp201079_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA et al (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611\u2013622.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201079_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1023\/A:1020464017021","volume":"73","author":"R Tandon","year":"2002","unstructured":"Tandon R (2002). Safety and tolerability: how do newer generation \u2018atypical\u2019 antipsychotics compare? Psychiatr Q 73: 297\u2013311.","journal-title":"Psychiatr Q"},{"key":"BFnpp201079_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10401230209149099","volume":"14","author":"R Tandon","year":"2002","unstructured":"Tandon R, Jibson MD (2002). Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 14: 123\u2013129.","journal-title":"Ann Clin Psychiatry"},{"key":"BFnpp201079_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1034\/j.1600-0447.2003.02078.x","volume":"107","author":"DM Taylor","year":"2003","unstructured":"Taylor DM (2003). Antipsychotics and QT prolongation. Acta Psychiatr Scand 107: 85\u201395.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp201079_CR31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.4088\/JCP.v65n0808","volume":"65","author":"DM Taylor","year":"2004","unstructured":"Taylor DM, Young CL, Mace S, Patel MX (2004). Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 65: 1076\u20131083.","journal-title":"J Clin Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp201079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201079","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:23:44Z","timestamp":1684455824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp201079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnpp201079"],"URL":"https:\/\/doi.org\/10.1038\/npp.2010.79","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}